Guggenheim Capital LLC boosted its stake in The Cooper Companies, Inc. (NYSE:COO) by 53.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 257,344 shares of the medical device company’s stock after purchasing an additional 89,339 shares during the quarter. Guggenheim Capital LLC owned about 0.52% of The Cooper Companies worth $56,070,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Virtue Capital Management LLC bought a new stake in The Cooper Companies in the fourth quarter valued at about $195,000. Jefferies Group LLC increased its holdings in The Cooper Companies by 147.2% in the fourth quarter. Jefferies Group LLC now owns 27,591 shares of the medical device company’s stock valued at $6,012,000 after purchasing an additional 16,429 shares during the last quarter. Caxton Associates LP increased its holdings in The Cooper Companies by 133.9% in the fourth quarter. Caxton Associates LP now owns 4,445 shares of the medical device company’s stock valued at $968,000 after purchasing an additional 2,545 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its holdings in The Cooper Companies by 1.1% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 238,386 shares of the medical device company’s stock valued at $51,940,000 after purchasing an additional 2,618 shares during the last quarter. Finally, Advisor Group Inc. increased its holdings in shares of The Cooper Companies by 30.8% in the fourth quarter. Advisor Group Inc. now owns 7,784 shares of the medical device company’s stock worth $1,696,000 after acquiring an additional 1,833 shares in the last quarter. Institutional investors and hedge funds own 98.53% of the company’s stock.
In related news, CEO Robert S. Weiss sold 36,769 shares of the stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $242.35, for a total transaction of $8,910,967.15. Following the completion of the transaction, the chief executive officer now directly owns 135,936 shares of the company’s stock, valued at $32,944,089.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Carol R. Kaufman sold 13,362 shares of the stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $243.88, for a total value of $3,258,724.56. Following the transaction, the executive vice president now directly owns 59,305 shares of the company’s stock, valued at $14,463,303.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,581 shares of company stock valued at $13,645,387. 1.60% of the stock is owned by corporate insiders.
NYSE:COO opened at $217.98 on Friday. The company has a quick ratio of 1.61, a current ratio of 2.83 and a debt-to-equity ratio of 0.75. The stock has a market cap of $10,844.02, a P/E ratio of 22.47, a PEG ratio of 1.74 and a beta of 0.62. The Cooper Companies, Inc. has a 52-week low of $194.55 and a 52-week high of $260.26.
The Cooper Companies (NYSE:COO) last posted its quarterly earnings data on Thursday, March 8th. The medical device company reported $2.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.51 by $0.28. The business had revenue of $590.00 million during the quarter, compared to the consensus estimate of $583.07 million. The Cooper Companies had a return on equity of 16.90% and a net margin of 7.83%. The Cooper Companies’s quarterly revenue was up 18.2% on a year-over-year basis. During the same period last year, the company earned $1.93 earnings per share. research analysts predict that The Cooper Companies, Inc. will post 11.83 earnings per share for the current year.
Several brokerages have issued reports on COO. Goldman Sachs began coverage on The Cooper Companies in a report on Wednesday. They issued a “neutral” rating and a $231.00 price target for the company. Oppenheimer set a $265.00 price target on The Cooper Companies and gave the stock a “hold” rating in a report on Thursday, March 29th. TheStreet downgraded The Cooper Companies from a “b” rating to a “c” rating in a report on Thursday, March 8th. BMO Capital Markets restated an “outperform” rating and issued a $280.00 price target (up from $277.00) on shares of The Cooper Companies in a report on Friday, March 9th. Finally, Stephens restated a “hold” rating and issued a $270.00 price target on shares of The Cooper Companies in a report on Friday, March 9th. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $264.18.
TRADEMARK VIOLATION NOTICE: This article was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/guggenheim-capital-llc-increases-position-in-cooper-companies-inc-coo.html.
The Cooper Companies Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Receive News & Ratings for The Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.